128 related articles for article (PubMed ID: 28486686)
1. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.
Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG
Ann Oncol; 2017 Aug; 28(8):1903-1909. PubMed ID: 28486686
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.
Kristensen G; Berg KD; Toft BG; Stroomberg HV; Nolley R; Brooks JD; Brasso K; Roder MA
J Clin Pathol; 2019 Oct; 72(10):696-704. PubMed ID: 31331953
[TBL] [Abstract][Full Text] [Related]
3. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.
Zhang AY; Chiam K; Haupt Y; Fox S; Birch S; Tilley W; Butler LM; Knudsen K; Comstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Ricciardelli C; Böhm M; Henshall S; Delprado W; Stricker P; Horvath LG; Kench JG
Int J Cancer; 2019 Mar; 144(5):1151-1159. PubMed ID: 30288742
[TBL] [Abstract][Full Text] [Related]
4. Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.
Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG
Prostate; 2016 Dec; 76(16):1491-1500. PubMed ID: 27473574
[TBL] [Abstract][Full Text] [Related]
5. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.
Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG
Prostate; 2011 Nov; 71(15):1638-45. PubMed ID: 21432866
[TBL] [Abstract][Full Text] [Related]
6. Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.
Brooks JD; Wei W; Pollack JR; West RB; Shin JH; Sunwoo JB; Hawley SJ; Auman H; Newcomb LF; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave ME; Lin DW; Nelson PS; Thompson IM; True LD; McKenney JK; Feng Z; Fazli L
Prostate; 2016 Nov; 76(15):1409-19. PubMed ID: 27325561
[TBL] [Abstract][Full Text] [Related]
7. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer.
Huang CY; Zhao JJ; Lv L; Chen YB; Li YF; Jiang SS; Wang W; Pan K; Zheng Y; Zhao BW; Wang DD; Chen YM; Yang L; Zhou ZW; Xia JC
PLoS One; 2013; 8(7):e69155. PubMed ID: 23935945
[TBL] [Abstract][Full Text] [Related]
9. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
10. Zinc-α-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population.
Xue Y; Yu F; Yan D; Cui F; Tang H; Wang X; Chen J; Lu H; Zhao S; Peng Z
Int J Mol Sci; 2014 Dec; 16(1):691-703. PubMed ID: 25561225
[TBL] [Abstract][Full Text] [Related]
11. AZGP1 is androgen responsive and involved in AR-induced prostate cancer cell proliferation and metastasis.
Cao R; Ke M; Wu Q; Tian Q; Liu L; Dai Z; Lu S; Liu P
J Cell Physiol; 2019 Aug; 234(10):17444-17458. PubMed ID: 30820960
[TBL] [Abstract][Full Text] [Related]
12. Salvage radiation therapy after radical prostatectomy: survival analysis.
Galla A; Maggio A; Delmastro E; Garibaldi E; Gabriele P; Bresciani S; Di Dia A; Stasi M; Gabriele D
Minerva Urol Nefrol; 2019 Jun; 71(3):240-248. PubMed ID: 30037205
[TBL] [Abstract][Full Text] [Related]
13. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract][Full Text] [Related]
14. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
15. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
[TBL] [Abstract][Full Text] [Related]
16. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
17. Development of a prediction model for mortality and cardiovascular outcomes in older adults taking into account AZGP1.
Huscher D; Ebert N; Soerensen-Zender I; Mielke N; Schaeffner E; Schmitt R
Sci Rep; 2021 Jun; 11(1):11792. PubMed ID: 34083628
[TBL] [Abstract][Full Text] [Related]
18. A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.
Severi G; FitzGerald LM; Muller DC; Pedersen J; Longano A; Southey MC; Hopper JL; English DR; Giles GG; Mills J
Cancer Med; 2014 Oct; 3(5):1266-74. PubMed ID: 24909936
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma.
Parris TZ; Kovács A; Aziz L; Hajizadeh S; Nemes S; Semaan M; Forssell-Aronsson E; Karlsson P; Helou K
Int J Cancer; 2014 Apr; 134(7):1617-29. PubMed ID: 24114735
[TBL] [Abstract][Full Text] [Related]
20. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy.
Lunger L; Retz M; Bandur M; Souchay M; Vitzthum E; Jäger M; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Koll F; Gschwend JE; Nawroth R; Heck MM
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):362-369. PubMed ID: 32978525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]